Inventiva Announces Temporary Trading Halt
Inventiva, a clinical-stage biopharmaceutical company known for developing oral therapies to combat metabolic dysfunction-associated steatohepatitis, has announced a temporary halt of its ordinary shares trading on Euronext Paris. This decision, which comes at the company's request, will begin at the market's opening hour, indicating something significant brewing within the company.
Context and Rationale for Trading Halt
The trading suspension was initiated in light of a public offering involving the issuance of new American Depositary Shares (ADSs). Each of these ADSs represents one ordinary share of Inventiva, with a nominal value of €0.01. The halt aims to ensure a smooth process for allocating shares to investors and disclosing the offering's pricing.
Expected Resumption of Trading
According to corporate officials, trading on Euronext Paris is anticipated to resume later the same day, at approximately 3:30 p.m. (CET). This timeframe correlates precisely with when the ADSs are set to commence trading on the Nasdaq Global Market, under the ticker symbol "IVA". Investors are keenly awaiting updates to navigate through this transitional phase.
About Inventiva and Its Innovations
Inventiva is committed to addressing the needs of patients suffering from MASH. The company is presently evaluating lanifibranor, an innovative pan-PPAR agonist. This treatment is undergoing pivotal Phase 3 clinical trials, specifically targeting adults afflicted with MASH, a progressive chronic liver condition affecting numerous individuals worldwide.
Company Growth and Market Presence
Inventiva maintains a robust position in the biopharmaceutical industry, with listings on Euronext Paris and the Nasdaq Global Market. It exemplifies a commitment to research and development, driving innovations in drug therapies that address significant health challenges. The ticker symbol for both markets is "IVA", solidifying its identity in the investment community.
Contact Information for Inquiries
Investors looking for more information can reach out through these channels:
- Inventiva
Pascaline Clerc
EVP, Strategy and Corporate Affairs
Email: media@inventivapharma.com
Phone: +1 202 499 8937 - ICR Healthcare
Media Relations: Alexis Feinberg
Email: inventivapr@icrhealthcare.com
Phone: +1 203 939 2225 - ICR Healthcare
Investor Relations: Patricia L. Bank
Email: patti.bank@icrhealthcare.com
Phone: +1 415 513 1284
Frequently Asked Questions
What is the reason for the trading halt of Inventiva’s shares?
The trading halt is in place to facilitate the company’s public offering of new ADSs, ensuring proper share allocation and pricing communication for investors.
When will trading resume on Euronext Paris?
Trading is expected to resume on the same day around 3:30 p.m. (CET), aligning with the ADSs set to trade on Nasdaq.
What is MASH and its significance?
MASH, or metabolic dysfunction-associated steatohepatitis, is a chronic liver disease that impacts many individuals globally, prompting the need for effective treatments developed by companies like Inventiva.
How can investors contact Inventiva for more information?
Investors can contact Inventiva through their designated representatives listed under company contact information for inquiries regarding the trading halt or any ongoing projects.
What is the ticker symbol for Inventiva on the stock exchange?
Inventiva is listed under the ticker symbol "IVA" on both Euronext Paris and the Nasdaq Global Market.
